Docetaxel added to androgen deprivation therapy (ADT) was the most cost-effective first-line regimen for patients with ...
For Julie Cohen, a diagnosis of multiple myeloma wasn't just a medical hurdle — it was a profound shift in perspective. Initially searching for a cure, she soon realized that navigating a high-risk, ...
March weather becomes a metaphor for survivorship as a mother describes anxiety, relief and uncertainty patients with cancer ...
February 2026 coverage highlighted combination EGFR therapy guidance, chemo-free treatment options, biomarker testing and survivorship lung health.
The FDA granted priority review to rusfertide, a potential therapy for polycythemia vera; a decision regarding approval is ...
CURE spoke with incoming ASCO president Dr. Deb Schrag on elevating the patient voice, humanism in care and why partnership shapes better cancer outcomes. Dr. Deb Schrag knows all about the importance ...
Adjuvant therapy with Imfinzi (durvalumab) and Imjudo (tremelimumab-actl) in patients with resected renal cell carcinoma was ...
Active surveillance (“watch and wait”) functioned as a strategy to monitor biology while preserving sequencing flexibility for subsequent therapies. Living long-term with cancer means learning to live ...
A phase 3 global trial is enrolling previously treated locally advanced/metastatic nonsquamous NSCLC to define DATROWAY efficacy and safety at scale. IDE034 is in open-label phase 1 ...
Induction Yervoy (ipilimumab) plus Opdivo (nivolumab) followed by consolidative chemoradiotherapy demonstrated bladder ...
The third and final day of the 2026 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium highlighted important developments in kidney cancer treatment, including combination ...
At 24 months overall survival was 62.8% with Welireg plus Lenvima versus 55.4% with Cabometyx. Median overall survival was 34 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results